Immunity and inflammation are key elements of the pathobiology of stroke, a devastating illness second only to cardiac ischemia as a cause of death worldwide. The immune system participates in the brain damage produced by ischemia, and the damaged brain, in turn, exerts an immunosuppressive effect that promotes fatal infections that threaten the survival of people after stroke. Inflammatory signaling is involved in all stages of the ischemic cascade, from the early damaging events triggered by arterial occlusion to the late regenerative processes underlying post-ischemic tissue repair. Recent developments have revealed that stroke engages both innate and adaptive immunity. But adaptive immunity triggered by newly exposed brain antigens does not have an impact on the acute phase of the damage. Nevertheless, modulation of adaptive immunity exerts a remarkable protective effect on the ischemic brain and offers the prospect of new stroke therapies. As immunomodulation is not devoid of deleterious side effects, a better understanding of the reciprocal interaction between the immune system and the ischemic brain is essential to harness the full therapeutic potential of the immunology of stroke.
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Inflammation affects the brain after stroke, and cells of the immune system, such as neutrophils and macrophages, have traditionally been used by neuropathologists and forensic pathologists to determine the approximate age of cerebrovascular lesions 1 . Although inflammation was commonly thought to be merely a reaction to tissue damage, it has been increasingly recognized as a key contributor to the pathophysiology of cerebrovascular diseases, especially stroke caused by arterial occlusion or ischemic stroke 2 . Recent evidence suggests that elements of the immune system are intimately involved in all stages of ischemic cascade (Box 1), from the acute intravascular events triggered by the interruption of the blood supply to the parenchymal processes leading to brain damage and the ensuing tissue repair. In turn, the ischemic brain, through the autonomic nervous system, exerts a potent suppressive effect on lymphoid organs that promotes intercurrent infections, a major determinant of stroke morbidity and mortality 3, 4 . Therefore, the immune system is closely involved on determining the fate of the ischemic brain and the survival of people after stroke. In multiple sclerosis, the classical inflammatory disease of the central nervous system (CNS), elements of innate and adaptive immunity are engaged in the post-ischemic brain 5 . Thus, molecular cues generated by cerebral ischemia activate components of innate immunity, promote inflammatory signaling and contribute to tissue damage. At the same time, these processes stimulate a potentially damaging adaptive immune response directed at antigens previously sequestered behind the blood-brain barrier (BBB). These recent developments warrant a reevaluation of the contribution of inflammation and immunity to stroke pathophysiology. This review will discuss the involvement of innate and adaptive immunity in ischemic brain injury and their impact on tissue damage and repair. Furthermore, we will examine the evidence for an adaptive cytotoxic response against newly exposed brain antigens and their role in the acute and chronic phase of the injury. Finally, we will evaluate the therapeutic opportunities afforded by modulation of the immune system and their potential pitfalls.
Inflammatory signaling in the early post-ischemic period Post-ischemic inflammation is characterized by an orderly sequence of events involving the brain, its vessels, the circulating blood and lymphoid organs. Inflammation is an integral part of the cascade of events triggered by ischemia and reperfusion (Box 1). The inflammatory process begins in the intravascular compartment immediately after arterial occlusion, when the ensuing hypoxia, changes in shear stress and production of reactive oxygen species (ROS) trigger the coagulation cascade, and lead to activation of complement, platelet and endothelial cells [6] [7] [8] [9] (Fig. 1) . The resulting intravascular formation of fibrin traps platelets and leukocytes, leading to microvascular occlusions 10, 11 . Within minutes after ischemia, the adhesion molecule P-selectin is translocated to the surface membrane of platelets and endothelial cells 12 , and proinflammatory signals are rapidly generated ( Table 1) . Oxidative stress in endothelial cells reduces the bioavailability of nitric oxide (NO), which is a potent vasodilator and an inhibitor of platelet aggregation and leukocyte adhesion 12 . Loss of the beneficial effects of NO exacerbates intravascular plugging and aggravates the ischemic insult by reducing blood flow to the ischemic territory 13, 14 . Furthermore, oxidative stress leads to constriction of pericytes, contractile cells that replace myocytes in capillaries, producing more microvascular occlusions 15 . Oxidative stress and inflammatory mediators also alter the permeability of the BBB, which increases the number of pinocytotic vesicles in the cytoplasm of endothelial cells, enhancing transendothelial transport 16 . Proteases are expressed in vascular cells and released by leukocytes, whereas junctional proteins that seal adjacent endothelial cells are downregulated, facilitating extravasation of proteins and cells through the paracellular route ( Fig. 1) 16 . In the perivascular space, ischemia and reperfusion activate perivascular ( Fig. 1) , activation of these receptors downregulates microglial cytokine, ROS and NO production 27 and suppresses the secretory response in mast cells 28, 29 . Therefore, ATP represents an early neuronal danger signal, promoting the inflammatory response of resident immune cells, whereas neurotransmitter release may oppose these changes and counteract inflammation.
Cell death and pattern recognition receptors in the post-ischemic brain. A different signaling landscape emerges after cells begin to die. A wide variety of molecular signals is released from the intracellular compartment or is generated by the action of lytic enzymes escaped from dead cells on matrix proteins (Fig. 2) . These so-called dangerassociated molecular pattern molecules (DAMPs) activate pattern recognition receptors, including Toll-like receptors (TLRs) and scavenger receptors, which are widely expressed on microglia, perivascular macrophages and brain endothelial cells 30 . DAMPs and purines act in concert to induce the expression of proinflammatory molecules in infiltrating leukocytes (Table 1) and to prime dendritic cells (DCs) for antigen presentation (Boxes 2 and 3) (Fig. 2) . Considering the high vascular density of the brain, inflammatory mediators released from parenchymal cells are likely to feed back on the vascular and perivascular compartments to reinforce and amplify the expression of cytokines, chemokines and adhesion molecules that drive the infiltration of blood-borne cells into the ischemic tissue. After neuronal death, loss of cell-to-cell interaction between neurons and microglia, which are kept quiescent in the normal state by contact with neurons, also promotes inflammatory signaling (Fig. 1) . For example, CD200, a surface protein expressed in neurons, interacts with its receptor CD200R on microglia, enforcing a resting phenotype 31 . Disruption of this interaction due to post-ischemic loss of CD200 (ref. 32 ) may promote microglial activation (Fig. 1) . Similarly, CX3CL1 (fractalkine), a cell surface-bound macrophages and mast cells. Mast cell degranulation releases vasoactive mediators, such as histamine, proteases and tumor necrosis factor (TNF), whereas activated macrophages release proinflammatory cytokines [17] [18] [19] [20] (Box 2) (Fig. 1) . These proinflammatory mediators contribute to the endothelial expression of adhesion molecules and to the BBB damage that promotes the infiltration of leukocytes (neutrophils, lymphocytes and monocytes) 19 .
Ischemic cell death sets the stage for innate and adaptive immunity As the ischemic cascade progresses (Box 1), cell death leads to a new phase of the inflammatory response (Fig. 2) . Dying and dead cells release 'danger signals' that activate the immune system 21 . Some of these signals, such as the nucleotides ATP and UTP, are released by cells under stress when the cell membrane is still intact and set the stage for the subsequent immune response 22 .
ATP and neurotransmitters. Extracellular ATP abundance increases within minutes after ischemia as a result of neuronal and glial depolarization or escape through damaged plasma membranes [23] [24] [25] . ATP is also released by vascular cells and blood cells and may promote intravascular coagulation and platelet aggregation 26 . High parenchymal ATP amounts activate P2X7 receptors in microglia, leading to release of proinflammatory mediators (Fig. 2) . Activated microglia develop many characteristics of macrophages, including ameboid morphology, migratory capacity, phagocytosis and major histocompatibility complex (MHC) class II-restricted antigen presentation (Box 3). At the same time, neurotransmitters release after ischemia and reperfusion may counteract the emerging inflammatory response. Microglia express a wide variety of neurotransmitter receptors, including AMPA, kainate, adrenergic, GABA B opioid and cannabinoid receptors 27 . With some exceptions 27 Figure 1 Early vascular, perivascular and parenchymal events triggered by ischemia and reperfusion. Hypoxia, ROS and changes in shear stress initiate the cellular events induced by ischemia and reperfusion. In the vessels lumen, ischemia and reperfusion lead to blood clotting, platelet aggregation and cytokine (IL-1a) release. Translocation of P-selectin on the surface of platelets and endothelial cells leads to platelet-leukocyte aggregation. Complement is activated, and arachidonic acid metabolites (AA) are released. In the vascular wall, upregulation of E-and P-selectin on endothelial cells provides a platform for low affinity leukocyte binding through interaction with glycoproteins expressed on leukocytes, for example, P-selectin glycoprotein ligand-1. Firm adhesion is obtained after endothelial expression of ICAM-1 interacting with leukocyte b2 integrins (LFA-1 and Mac-1). Loss of NO promotes vasoconstriction and enhances leukocyte and platelet aggregation. MMP activation could lead to BBB breakdown and matrix proteolysis, facilitating leukocyte extravasation. In the perivascular space, chemotactic complement subunits (C5a) acting on mast cell complement receptors (CD88) leads to degranulation and release of histamine and proteases, contributing to BBB leakiness. Cytokines (TNF, IL-1b) are produced by mast cells and perivascular macrophages, providing further signals to guide leukocyte migration across the vessel wall. In the brain parenchyma, injured cells release purines (ATP), which act as early proinflammatory signals leading to production of cytokines and chemokines. Disruption of neuronal-microglial interaction (CX3CL1, CD200) and increases in extracellular glutamate (Glu) acting on microglial GluR1 metabotropic receptor 27 also contribute to the proinflammatory milieu.
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Stroke and adaptive immunity. Antibodies against CNS antigens develop after ischemic stroke, suggesting a humoral immune response to the injury, and circulating T cells become sensitized against CNS antigens, such as myelin basic protein (MBP) and related peptides ( Table 2) . Antigen-presenting cell (APC) numbers are reduced in the periphery and increased in the ischemic brain both in rodent and human stroke [35] [36] [37] [38] . The accumulation of APCs coincides with the peak of lymphocytic infiltration and is associated with expression of MHC class II molecules and the co-stimulatory molecule CD80 35, 37, 38 , findings suggestive of antigen presentation (Box 3). Support for involvement of adaptive immunity also comes from studies on the role of lymphocytes in rodent models of focal cerebral ischemia. Ischemia leads to infiltration of the major lymphocytes subtypes into the ischemic brain 37 (Box 3), and increasing evidence suggests that they contribute to ischemic injury ( Table 2 and Fig. 3) . In fact, lymphocyte-deficient mice are protected from ischemic damage 39, 40 . The protection has been attributed to T cells, because B cell-deficient mice or lymphocyte-deficient mice reconstituted with B cells are still protected from injury ( Table 2) . gdT cells also have been shown to contribute to the injury by releasing the proinflammatory cytokine IL-17 (ref. 41) (Fig. 3) . In contrast, T regulatory (T reg ) cells are protective in the late stage of cerebral ischemia, an effect evident only if the injury is small 42, 43 . Additional evidence in favor of the involvement of cell-based adaptive mechanisms in stroke damage was provided by studies in which animals were tolerized against myelin-derived peptides ( Table 2) . Repeated mucosal administration of myelin antigens (tolerization) before arterial occlusion protects rodents from ischemic brain injury 44 . Although tolerization is antigen specific, its beneficial effects are not restricted to immune responses directed at the inducing antigen, but are instead more widespread, a phenomenon termed bystander suppression 44 . The protection can be induced in naive mice by adoptive transfer of splenocytes or CD4 + T cells from chemokine constitutively expressed by neurons, suppresses microglial activation through its microglial receptor CX3CR1. Thus, after neuronal injury, loss of CX3CL1 results in enhanced microglial activation in several inflammatory disease models 33 . In addition, increasing concentrations of extracellular glutamate activate metabotropic glutamate receptors on microglia, leading to a proinflammatory phenotype 34 ( Fig. 1) . Therefore, as neuronal death develops in the ischemic core and spreads to the penumbra, the loss of the immunosuppressive effect afforded by neurotransmitter release and neuron-microglia interaction may also foster post-ischemic inflammation.
Collectively, these observations suggest that the inflammatory response after ischemia and reperfusion starts at the vascular level, driven by nontranscriptional events triggered by hypoxia, shear stress and ROS production. As ischemia damages the brain tissue, danger signals are released first from cells under stress and then from necrotic cells. Concomitant with the loss of immunosuppressive mechanisms, these signals activate purinergic receptors and pattern recognition receptors, which induce an inflammatory response in resident brain cells and infiltrating leukocytes, resulting in inflammation-induced cell death (Box 4).
Does adaptive immunity contribute to ischemic brain injury?
Danger signals released from damaged cells also promote the presentation of tissue antigens that were previously hidden by the BBB or that develop as a result of the breakdown of cell membranes 21 (Fig. 2) . Antigen presentation leads to the development of cellular and humoral immunity directed against the antigens (Box 3). This adaptive immune response has the potential of inducing autoimmunity against the organ in which the cell death occurred, as described in the heart (Dressler's syndrome), eye (sympathetic ophthalmia) and pancreas (diabetes) 21 . Furthermore, the damaging effect of adaptive immunity is well established in multiple sclerosis and in models of autoimmune demyelina- AG, astroglia; Circ, plasma; EC, endothelial cells; Leuk, leukocytes; Macr, macrophages; MC, mast cells; MG, microglia; Neu, neurons; PLT, platelets; PVM, perivascular macrophages. BDNF, brain-derived growth factor; COX-2, cyclooxygenase-2; EPO, erythropoietin; FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GDNF, glial cell-derived neurotrophic factor; HB-EGF, heparin-binding epidermal growth factor-like growth factor; LOX, lipoxygenase; Mac-1, macrophage-1 antigen; MIP, macrophage inflammatory protein; NGF, nerve growth factor; PTGES, prostaglandin E2 synthase-1; RANTES, regulated upon activation, normally T-expressed, and presumably secreted; VCAM-1, vascular adhesion molecule 1; VLA-1, very late activation antigen-1 (see Supplementary Table 1 for references).
result from suppression of autoreactive T cells targeted against myelin 49 . Although RTLs may not bind T cells-but rather APC and platelets 50 the findings suggest a role of cellular immunity in the mechanisms of ischemic brain injury.
Despite the evidence supporting an autoimmune response against the post-ischemic brain, there are inconsistencies with the hypothesis that classical adaptive immunity contributes ischemic brain injury. The temporal profile of the involvement T cells in brain damage is not consistent with established concepts of adaptive immunity 51 (Fig. 3) . Thus, the protective effect observed in lymphocyte-deficient mice or afforded by blocking postischemic trafficking of T cells into the ischemic brain tolerized animals 45, 46 , suggesting the involvement of cellular immune mechanisms. Examination of T cell function indicated that activation of tolerized T cells by the antigen unveiled by the stroke induces a T H 2 cytokine response (Box 3) 45, 47, 48 . The effect has been attributed to IL-4 and IL-10 production, which favors the formation of transforming growth factor-b (TGF-b)-secreting T reg cells 45, 46, 48 . Other studies have found that administration of recombinant T cell receptor ligand (RTL), consisting of a1 and b1 domains of MHC class II complex bound to a myelin peptide antigen (myelin oligodendrocyte glycoprotein (MOG)-35-55), reduces stroke volume in focal ischemia 49 . The protective effect is associated with reduction of infiltrating inflammatory cells and may
BOX 1 From ischemia to infarction: the ischemic cascade
Brain function depends on the continuous delivery of oxygen and glucose through blood flow, and interruption of the cerebral blood supply leads to irretrievable brain damage 2 . Ischemic damage results from a cascade of cellular and molecular events triggered by sudden lack of blood flow and subsequent reperfusion of the ischemic territory. Neurons are more vulnerable than glia and vascular cells and become quickly dysfunctional or die when exposed to hypoxia-ischemia 123 . In ischemia produced by occlusion of the middle cerebral artery, the most common type of stroke, the damage is more rapid and severe in the center of the ischemic territory (ischemic core), where flow is lowest 2 . At the periphery of the ischemic region, the so-called ischemic penumbra, neuronal damage develops more slowly because blood flow arising from adjacent vascular territories (collateral flow) keeps cerebral perfusion above the threshold for immediate cell death 2 . In the ischemic core, the major mechanism of cell death is energy failure-without oxygen and glucose, neurons cannot generate the ATP needed to fuel the ionic pumps that maintain the ionic gradient across the neuronal membrane, mainly the Na + -K + ATPase 123 . Consequently, massive Na + and Ca 2+ cytoplasmic accumulation leads to swelling and degeneration of the organelles, loss of membrane integrity and dissolution of the cell (necrotic cell death) 123 . In the ischemic penumbra, the flow reduction is not sufficient to cause energy failure, and neurons remain viable for a prolonged period of time after the insult, but the neurons are stressed and critically vulnerable to pathogenic events that may tip their fragile metabolic balance 2 . Excessive extracellular accumulation of glutamate is a major factor contributing to the demise of the ischemic penumbra. The resulting overactivation of the NMDA subtype of glutamate receptors leads to cytoplasmic accumulation or Ca 2+ , which activates Ca 2+ -dependent enzymes, including the proteases calpain and caspase, and enzymes producing nitric oxide, free radicals and arachidonic acid metabolites 123 . These events lead to necrosis or programmed cell death depending on the intensity of the insult and the metabolic state of the neurons 2, 123 . Injured and dying cells have a key role in post-ischemic inflammation because they release danger signals that activate the immune system.
The mechanisms of ischemic stroke have been studied in in vitro and in vivo models of cerebral ischemia 2, 123 ; however, these models do not recapitulate all the features of human stroke and may introduce important confounders, such as anesthesia and surgical trauma. Furthermore, differences in vascularization and immune responses in the human brain (Box 2) may alter the initiation and evolution of the tissue damage. Nevertheless, the core features of stroke pathophysiology are comparable between animals and humans, and animal models of cerebral ischemia remain a mainstay of preclinical stroke research 124 . Release of nucleotides (ATP, UTP) from injured cells, including neurons, activates purinergic receptors on microglia and macrophages and leads to production of proinflammatory cytokines 25 . Although most of these cytokines are transcriptionally induced, IL-1b and IL-18 are processed from their propeptides by the activity of interleukin-1-converting enzyme (ICE; caspase 1). ICE is embedded in a multiprotein complex (NLRP3, or inflammasome) and is activated by microglial P2X7 receptors 108 . Ischemic cell death leads to the formation of DAMPs, which activate TLRs, especially TLR2 and TLR4 (ref. 21) . DAMPs released by ischemia include high-mobility group protein B1, an intracellular DNA binding protein released after cellular injury, heat shock protein 60 and b-amyloid (Ab), among others 30 . TLRs, in concert with scavenger receptors such as CD36, upregulate proinflammatory gene expression through the transcription factor nuclear factor-kB 30, 109 . DAMPs are also derived from matrix breakdown by lytic enzymes released from dead cells and by the action of ROS on lipids. The cytokine production and complement activation resulting from these events leads to increased leukocyte infiltration and enhances tissue damage, which, in turn, produces more DAMPs. Antigens unveiled by tissue damage are presented to T cells, setting the stage for adaptive immunity.
r e v i e w thrombotic actions leading to microvascular occlusions 52 . These effects would be deleterious by preventing reperfusion and by compromising collateral flow after ischemia and reperfusion. But lack of lymphocytes does not improve post-ischemic cerebral blood flow at least in the acute phase 53 , nor does it suppress thrombus formation 40 . Therefore, effects of lymphocytes altering microvascular perfusion or patency seem unlikely. Another possibility is that natural killer T (NKT) or gdT cells, T cells that have a simplified T cell receptor (TCR) and may not require antigen processing and MHC presentation, as well as NK cells (Box 3), are responsible for these early cytotoxic effects of lymphocytes. In support of this hypothesis, NKT cells are not present in recombinationactivating gene 1 (Rag1) -/-mice and severe combined immunodeficient mice 54 , and they could contribute to explain the early neuroprotection observed in these models of lymphocyte deficiency 39, 40 . However, CD1-deficient mice lack NKT cells and are not protected from ischemic injury 24 h after middle cerebral artery occlusion 40 , suggesting that NKT cells may not be involved in the early phase of the injury. gdT cells have been implicated in ischemic brain injury, but their involvement seems restricted to the late phase of cerebral ischemia (4 d) 40, 41 . Considering the limited number of studies available, the involvement of NK, NKT and gdT cells, lymphocyte subtypes that act in a fashion akin to innate immunity, needs further exploration. occurs 24-48 h after ischemia 40 , whereas adaptive responses require an interval of 7-10 d from antigen presentation to the clonal expansion of autoreactive T cells and immune attack on the target organ 51 (Box 3). Furthermore, reconstitution of lymphocyte-deficient mice with T cells targeting non-CNS antigens worsens ischemic damage, and mice lacking co-stimulatory molecules essential for antigen-specific T cell response are not protected from ischemia 40 . It is also surprising that, unlike autoimmune responses in other organs where there is a prevalence for either T helper or T effector cell participation, both CD4 + and CD8 + T cells are involved in ischemic injury 52 . Collectively, these observations argue against an autoimmune attack on the brain resulting from presentation of CNS antigen released by the stroke.
The lymphocyte puzzle. If lymphocytes do not mediate an autoimmune attack on the brain, how do they contribute to the early phase of ischemic brain injury? One possibility is that these cells participate in the cerebrovascular dysfunction occurring after ischemia or have pro- Figure 3 Deleterious and beneficial roles of T cells in stroke. In the acute phase of cerebral ischemia, unprimed T cells contribute to tissue damage in an antigen-independent manner (innate immunity), possibly through IFN-g 110 and ROS 111 (top left). gdT cells, activated by IL-23 released from microglia and macrophages, produce the cytotoxic cytokine IL-17 and contribute to acute ischemic brain injury 41 . However, T cells can also be protective. TGF-b produced by neurons, glia, or microglia and macrophages promotes the development of T reg cells secreting the protective cytokine IL-10 and inhibits T H 1 and T H 2 responses. T reg cells are protective in models of cerebral ischemia 42 . Induction of mucosal tolerance with CNS antigens produces an adaptive response, which leads to the establishment of autoreactive T H 2 cells producing IL-10 (ref. 48) and T reg cells producing IL-10 and TGF-b 107 is highly protective in experimental stroke (bottom right). Although there is no evidence that adaptive immunity contributes to acute ischemic brain injury, weeks and months after stroke, autoreactive CD4 + and CD8 + T cells targeting CNS antigens could develop (top right). The resulting cell death could play a part in the delayed brain damage and atrophy that occur after stroke 83 .
Katie Vicari r e v i e w reorganization of the injured brain. The factors governing resolution of inflammation and the reestablishment of tissue homeostasis are still poorly understood, particularly in brain. Increasing evidence suggests that resolution of inflammation is not a passive process due to exhaustion of the signaling; instead, it is orchestrated by the interplay of a large number of mediators that actively suppress the inflammatory response 55 . Major steps in the process include removal of dead cells, development of an anti-inflammatory milieu and generation of prosurvival factors fostering tissue reconstruction and repair 55, 56 .
Clearing dead cells. Microglia and infiltrating macrophages constitute the predominant phagocytes removing dead cells and tissue debris after stroke 57, 58 , a process orchestrated by 'find me' and 'eat me' signals. Find-me signals, including purines released from injured cells and chemokines, attract microglia and macrophages to the site of injury 59, 60 (Fig. 4) . These phagocytic cells are then presented with eat-me signals Collectively, these studies suggest that, although an antigen-specific immune response may develop after stroke, evidence showing that autoreactive T cells can attack the brain tissue after CNS antigens against which they were sensitized are exposed by ischemic damage is lacking. Lymphocytes have a role in the development and progression of the injury, but how they exert their powerful effect does not conform to the tenets of classical autoimmunity. The role of NK, NKT and gdT cells, which could contribute to the acute phase of the injury, needs further exploration. Similarly, considering the evidence for humoral immune responses in stroke (Table 2), the contribution of B cells to the damage needs a more in-depth assessment.
Resolution of inflammation and tissue repair
Post-ischemic inflammation is a self-limiting process that eventually subsides and prepares the terrain for the structural and functional Cerebral ischemia engages both innate and adaptive immunity, the two main braches of the vertebrate immune system 51 . The innate system is germline encoded and rapidly activated, and it relies on low-affinity receptors to gain wide-ranging target recognition. The adaptive system is based on high-affinity receptors, including T cell receptors and immunoglobulins, which are randomly generated by somatic mutations. In contrast to the innate system, adaptive immunity needs antigen-driven clonal cell expansion, a process that requires several days, and retains a memory of this antigen exposure 51 . Although specific cell types are predominantly associated with one of the two branches, there is considerable overlap between the role of these cells in innate and adaptive immunity. Here we describe cells predominantly associated with innate immunity. Lymphocytes are described in Box 3.
Microglia derive from the hematopoietic system and constitute the innate immune cells of the CNS 125 . Resting microglia survey the brain parenchyma through continuous extension and retraction of their processes. Microglia contribute to post-ischemic inflammation by producing TNF, IL-1b, ROS and other proinflammatory mediators ( Table 1 and Fig. 1 ). However, they also contribute to the resolution of inflammation and tissue repair by producing IL-10 and TGF-b, as well as several growth factors, including IGF-1 ( Table 1 and Fig. 4 ).
Perivascular macrophages are confined to the space between the vascular basement membrane and the brain surface (glia limitans) and, unlike microglia, are continuously replenished by hematogenous precursors 126 . Macrophages can be classified into two groups: M1 macrophages that produce proinflammatory cytokines (IL-1b, IL-12, IL-23 and TNF), chemokines, ROS and NO, promoting a T H 1 immune response (Box 3), and M2 macrophages that produce anti-inflammatory cytokines (IL-10 and TGF-b), IL-1ra and arginase 127 . After cerebral ischemia, cytokines produced by perivascular macrophages are thought to drive the infiltration of inflammatory cells 19 .
Mast cells are found in meninges and cerebral blood vessels. Mast cells granules store vasoactive substances (histamine), cytokines (TNF), anticoagulants (heparin) and proteases (tryptase, chymase, MMP2 and MMP9) 17, 18 . In addition, mast cells are capable of phagocytosis and antigen presentation and can modulate the adaptive immune response 128 .
BOX 2 Cells of the innate immune system
Blood monocytes are direct precursors of tissue macrophages. At least two different monocyte populations have been described in humans and mice according to their surface markers and function. 'Classical' monocytes produce the antiinflammatory cytokine IL-10 when challenged with LPS, whereas 'proinflammatory' monocytes produce TNF. After cerebral ischemia, inflammatory monocytes are rapidly recruited to the site of injury, where they give raise to macrophages and DCs 35 .
Dendritic cells are specialized APCs that constitute the main interface between innate and adaptive immunity (Box 3). In the normal brain, DCs are associated with meninges, choroid plexus and the cerebrospinal fluid. Cells expressing DC markers (CD11c, MHC class II) appear in the brain parenchyma after focal ischemia and originate from resident and blood-borne cells 35 .
Neutrophils are secretory and phagocytic cells of the innate immune system and carry different types of cytoplasmic granules and secretory vesicles. Major proinflammatory molecules stored in granules and vesicles include iNOS, NADPH oxidase, myeloperoxidase, MMP-8, MMP-9, elastase and cathepsins. After cerebral ischemia, neutrophils adhere to the cerebral endothelium and transmigrate into the tissue 12 . Vesicle and granule exocytosis is induced after receptor engagement, such as binding to E-selectin on endothelial cells and IL-8 stimulation 129 .
Is the immune system comparable in rodents and humans? Circulating neutrophils predominate in humans (50-70%), whereas lymphocytes predominate in rodents (75-90%) 130 . Several immune-related molecules, such as iNOS, P2X7, TLR2, antigen-presenting proteins, co-stimulatory molecules, immunoglobulins and chemokines, are differentially expressed in mice and humans or present in one species and not the other 130 . Human endothelial cells can present antigens to resting CD4 + and CD8 + T cells, whereas mouse endothelial cells can only activate CD8 + T cells 131 . Consequently, the immune responses initiated by vascular pathologies may differ quantitatively and qualitatively between humans and mice. The impact of these differences needs to be considered when translating findings obtained from rodent models of cerebral ischemia to human stroke. r e v i e w recovery has also been highlighted by studies in which the transcriptome of sprouting neurons indicated involvement of MHC I class molecules and complement subunits 66 .
This evidence indicates that cells of the immune system have a fundamental role in all the phases of post-ischemic brain recovery. But the limited data available provide only a glimpse into the complex sequence of events that reestablish the structural and functional homeostasis of the brain after stroke. Additional studies on recently identified mediators instrumental to inflammation resolution and tissue repair, such as lipoxins, resolvins, protectins, progranulins and cyclopentenone prostaglandins ( Table 1 and Fig. 4) 55, 56 , are needed to fully elucidate the role of the immune system in brain repair after stroke.
Stroke and systemic immunity
Concomitant with the inflammatory response involving the brain, immunological changes are also observed in the blood, bone marrow, spleen and other lymphoid organs 3, 73 . Genome profiling of peripheral blood in individuals after stroke has demonstrated characteristic patterns of inflammatory gene expression that can help determine the cause of ischemic stroke 74 , reflecting the specificity of the systemic inflammatory response to brain injury. In rodent models, as in people with ischemic stroke, white blood cell count and expression of cytokines and inflammatory markers are increased within hours after ischemia [75] [76] [77] [78] . Such an acute-phase response is followed within 1 or 2 d by a marked immunodepression, especially in individuals with large strokes, characterized by lymphopenia, reduced functional activity of monocytes, upregulation of anti-inflammatory cytokines, lymphocyte apoptosis and splenic atrophy 78, 79 . These immunological changes are associated with a higher tendency to respiratory and urinary tract infections, which are responsible for considerable morbidity and mortality in people after stroke 3, 4 . Infections tend to occur in patients with larger stroke and associated with dying or dead cells (Fig. 4) .
TGF-β, IL-10 and the anti-inflammatory milieu. TGF-b and IL-10 are pleiotropic immunoregulatory cytokines that have a crucial role in the development of the anti-inflammatory milieu associated with tissue repair (Fig. 4) . The production of these cytokines is promoted by phagocytosis and occurs in concert with the removal of dead cells 56 . TGF-b, which is upregulated after ischemia primarily in microglia and macrophages, has neuroprotective properties and profound effects on immune cells. Although TGF-b is well known for its proinflammatory effects, it can also suppress inflammation by inhibiting T helper type 1 (T H 1) and T H 2 responses and promoting T reg cell development 61 . Similarly, the immunoregulatory cytokine IL-10, produced by multiple cell types, including T reg cells 42 , has both neuroprotective and antiinflammatory activities (Fig. 4) . Therefore, post-ischemic production of TGF-b and IL-10 can facilitate tissue repair by promoting the resolution of inflammation and exerting direct cytoprotective effects on surviving cells in the ischemic territory.
Growth factors. Post-ischemic production of growth factors helps to establish an environment that is favorable to neuronal sprouting, neurogenesis, angiogenesis, gliogenesis and matrix reorganization [62] [63] [64] . Inflammatory cells, as well as neurons and astrocytes 65, 66 , are capable of producing a vast array of growth factors ( Table 1) . For example, microglia are required for the full expression of insulin-like growth factor 1 (IGF-1) 67 , a key factor in post-ischemic neuronal sprouting 66 , whereas reactive astrocytes are required for functional recovery after stroke 68 . Vascular endothelial growth factor (VEGF), which is crucial for post-ischemic angiogenesis, is produced by reactive astrocytes 69 , and its action may require neutrophil matrix metalloproteinases (MMPs), suggesting a link between inflammatory cells and angiogenesis 70 . But VEGF administration early after ischemia or in excessive doses may enhance the damage 71, 72 . The role of inflammatory signaling in brain Eat-me signals include UDP, which acts on P2Y6 receptors to stimulate microglial phagocytosis 112 , and phosphatidylserine (PtdSer), which is translocated to the outer leaflet of the plasma membrane of apoptotic cells 112 . PtdSer-binding proteins involved in the clearance of dead cells include milk fat globule epidermal growth factor 8 protein on microglia 113 and T cell immunoglobulin and mucin domain-containing molecule 4 (TIM4) on macrophages 112 . Immunoglobulins directed against CNS antigens, which appear after stroke ( Table 2) , may also promote phagocytosis by engaging Fc receptors on phagocytic cells. Phagocytosis promotes secretion of IL-10 and TGF-b 56 , which, in turn, suppress antigen presentation, promote T reg formation, inhibit expression of adhesion molecules in endothelial cells and production of proinflammatory cytokines 61 . TGF-b and IL-10 are also neuroprotective 114, 115 and may facilitate brain repair processes. In addition, lipoxins, resolvins and protectins, metabolites of arachidonic acid and omega-3 fatty acids that play an active part in the resolution of inflammation in other organs 55 , could also contribute to suppress postischemic inflammation. Growth factors and MMPs produced by endothelial cells, neurons, astrocytes, oligodendrocytes and microglia are key molecules driving tissue reorganization and repair 63, 116 .
Katie Vicari r e v i e w survivors have dementia, often associated with brain atrophy 83 . The bases for the cerebral atrophy are not entirely clear, but immunological mechanisms triggered by the stroke cannot be discounted. Pathological studies have shown an inflammatory infiltrate that persists for years after the stroke. For example, mononuclear cells, perivascular cuffing and macrophages can be found, respectively, in 42%, 44% and 75% of brains with stroke in a large series 1 , and T cells and DCs are observed in 'old' strokes 38 . Nevertheless, these focal inflammatory changes have not been linked to post-stroke immunosuppression or dementia, and their pathogenic significance remains uncertain. On the other hand, immunosuppression after stroke is deleterious in that it increases the incidence of infections, a major determinant of poor neurological outcome, morbidity and mortality 3, 4 . Acute infection could also negatively affect stroke outcome by upregulating costimulatory molecules and promoting antigen presentation 21 . This possibility is supported by studies in which bacterial lipopolysaccharide (LPS) administered at the time of reperfusion to simulate infection after stroke, worsens the outcome of experimental stroke 84 and increases post-ischemic brain atrophy assessed 1 month after stroke 85, 86 . The with low CD4 + lymphocyte counts and elevated plasma levels of IL-10 and IL-6, reflecting immunodepression 80 . How these systemic immune changes are mediated is not completely understood, but there is evidence that sympathetic activation and the attendant release of stress steroids and catecholamines are involved 3, 4 . Thus, cortisol and catecholamines plasma levels are elevated in people after stroke most susceptible to infection 81 , and steroid antagonists and the b-adrenergic receptor antagonist propanolol counteract lymphocyte apoptosis and infection propensity after stroke in rodent models 82 .
Bright and dark sides of post-stroke immunosuppression
What is the biological importance of immunodepression after stroke? On the one hand, the lymphopenia and immunosuppression may limit the development of autoreactive T cells targeted to CNS antigens and dampen a potential autoimmune attack on the brain 3, 4 . The relative rapidity of the development of ischemic brain injury is not consistent with the temporal profile of an adaptive response against the brain; however, it is conceivable that sensitization to CNS antigens may be involved in the long-term outcome of the stroke (Fig. 3) . About 30% of stroke Lymphocytes are key cells in innate and adaptive immune responses. B cells are responsible for humoral immune responses characterized by the production of antibodies that attack and neutralize specific antigens 51 . T cells are involved in cellular immunity, in which extraneous antigens are suppressed by a cytotoxic cellular response. T cells express the glycoprotein CD4 or CD8 on their surface, a feature that determines their function and fate.
Antigen presentation. Antigen presentation is performed by APCs, mainly DCs and macrophages 51 , and is central to adaptive immunity. APCs patrol the environment, and when they recognize a foreign antigen, they degrade it into peptides, some of which are then assembled with MHC class II molecules and displayed on the APC surface 51 . The MHC class II-antigen complex is recognized by the TCR of CD4 + T cells, and this interaction in the presence of appropriate co-stimulatory molecules on APCs (B7-1, B7-2) and T cells (CD28) results in T cell activation. TCRs include either ab chains or gd chains, immunoglobulin-like proteins consisting of variable and fixed regions 51 γδT cells. gdT cells are a subset of effector lymphocyte with a TCR comprising gd chains and particularly enriched in mucous membranes 134 . Like NKT cells, these cells recognize nonpeptide antigens and react to danger signals produced by stressed cells 134 . gdT cells can exert different functions depending on the context in which they operate, ranging from cytolysis to antigen presentation, immunoregulation and production of growth factors 135 . In cerebral ischemia, gdT cells have been implicated in both cytotoxicity and protective immunomodulation. r e v i e w tory signaling, such as complement, TLR or scavenger receptors, is highly protective in experimental models (Supplementary Table 1) . Furthermore, minocycline, an agent with multiple neuroprotective actions, including broad anti-inflammatory properties, has shown promise in clinical trials 95 (Table 3) .
Immunomodulation and T cell-based approaches. Another strategy is to develop approaches in which the immune system is directed to suppress the deleterious effects of inflammation while enhancing its protective potential.
Ischemic tolerance provides an example of protective immunomodulation. Ischemic tolerance or preconditioning is a phenomenon in which a sublethal injurious stimulus protects an organ against a subsequent lethal stimulus. For example, a short nondamaging ischemic insult to the brain (local preconditioning) or other organs (remote preconditioning) protects the brain from a subsequent damaging ischemic insult 2, 96 . Although ischemic tolerance is known to protect the brain by simultaneously suppressing multiple pathways in the ischemic cascade 2 , modulation of the post-ischemic immune response has emerged as one of its key effector mechanisms 30, 97 . Similarly, administration of low doses of LPS induces tolerance and protects the brain from ischemic damage 26 . In this case, post-ischemic TLR4 signaling is redirected toward production of interferon-b (IFN-b) , which, in turn, reprograms the immune system to suppress the production of proinflammatory cytokines and the infiltration of inflammatory cells 98 . But nuclear factor-kB-dependent inflammatory mediators, such as IL-1, TNF, inducible nitric oxide synthase (iNOS)-derived NO and ROS, are also required for the full expression of the tolerance [99] [100] [101] [102] , indicating that the protection does not rely just on the suppression of deleterious inflammatory mediators but also on a fine balance between pro-and anti-inflammatory signaling. One of the challenges is therefore to learn how to modulate the immune system to replicate the beneficial inflammatory milieu induced by preconditioning. Tolerization may provide the opportunity to achieve this goal. Induction of immune tolerance through mucosal exposure to myelin antigens or E-selectin promotes a protective T H 2 response, which acts through multiple pathways to suppress the deleterious effects of inflammation 47 . As tolerization must be established before injury, this approach, like preconditioning, would be more appropriate for stroke prevention in high-risk individuals than acute stroke treatment. Another strategy may be the administration of RTL ( Table 3 ), given that it suppresses the infiltration of inflammatory cells and provides neuroprotection even when administered after the onset of cerebral ischemia 49 . Similarly, administration of the immunomodulatory co-polymer Poly-YE ameliorates the neurological deficits produced by cerebral ischemia, an effect attributed to increased production of growth factors and hippocampal neurogenesis 103 . The full translational potential of treatments based on immunomodulation has not been established-therapeutic window, efficacy in effect is associated with increased expression of B7.1, a co-stimulatory molecule needed for efficient antigen presentation (Box 3), as well as T cell sensitization against CNS antigens and a T H 1 cytokine response 85, 86 . Therefore, immunosuppression after stroke is detrimental by increasing the incidence of systemic infections and, possibly, by promoting antigen presentation and autoimmunity against the brain, which may worsen the long-term sequelae of the stroke.
Bench to bedside: trials, tribulations and promising therapies Ischemic stroke remains an enormous therapeutic challenge. Currently, thrombolysis with tissue plasminogen activator is the only effective therapy, but, owing to the narrow therapeutic window of less than 4.5 h and safety concerns, fewer than 5% of stroke patients receive this treatment 87 . Among the potential therapeutic approaches targeting the ischemic cascade (Box 1), preclinical studies in rodent models suggest that suppression of inflammation offers unique advantages. First, these treatments have an extended therapeutic window and are effective when administered up to 12-24 h after stroke 88, 89 . Therefore, they could be used in patients who fail the time window for thrombolysis. Second, as suppression of inflammation is also beneficial in models of cerebral hemorrhage 90 , concerns about worsening brain injury in patients in whom hemorrhagic stroke has not been excluded would be minimized and early treatment by emergency medical teams would become feasible. Finally, considering that the inflammation is particularly deleterious in ischemia associated with reperfusion 91, 92 , suppression of inflammation would be a fitting complement to reperfusion therapy using thrombolytics or intravascular clot removal.
Although these considerations are based on animal models, which may not recapitulate in full the human disease (Box 1), inflammation is a crucial pathogenic component of human stroke and remains an attractive target for therapeutic intervention.
Anti-inflammatory agents. Blocking antibodies directed against adhesion molecules (for example, intracellular adhesion molecule-1 (ICAM-1) or macrophage-1 antigen) or recombinant neutrophil inhibitory factor have not been effective in clinical trials 93 . In the case of the ICAM-1 trial, the negative outcome has been attributed to deleterious immunoactivation resulting from administration of a mouse antibody to humans, as reproduced in an experimental study in which mouse antibodies to rat ICAM-1 were administered to rats 94 . Although there also might be other reasons for these failures 93 , a probable contributing factor is that post-ischemic inflammation acts through multiple redundant pathways that cannot be effectively suppressed by blocking a single cytokine or adhesion molecule, as attempted in these clinical trials. Thus, neutralizing upstream mediators of the signaling cascade or blocking multiple inflammatory pathways would be more effective ( Table 3) . For example, blocking upstream components of inflamma- r e v i e w suppression of inflammation. Furthermore, in light of stroke-induced immunosuppression, the infectious complications of therapies suppressing inflammation also need to be taken into account (Table 3) . Therapies based on immunomodulation, in which the overall immune response is deviated from a T H 1-to a T H 2-type response, also have a dark side. In models of multiple sclerosis, tolerization with myelin antigens induces a protective T H 2 response in the acute phase, but, in the long term, such T H 2 response promotes B cell differentiation and leads to a humoral attack against myelin that worsens the neurological outcome 106 . Worsening in the chronic phase has also been reported in tolerization applied to models of cerebral ischemia 107 . Therefore, the delayed effects of humoral immunity could counteract the short-term benefit of suppression of cellular immunity. A more complete understanding of the immunology of stroke would enable the development of targeted approaches to selectively suppress the deleterious effects of inflammation.
Conclusions
Immunity and inflammation are an integral part of the pathogenic processes triggered by ischemia and reperfusion. Inflammatory signaling is responsible for early molecular events triggered by the arterial occlusion and that culminate in the invasion of the brain by blood-borne leukocytes. Although its ultimate goal is to reestablish homeostasis, inflammation inflicts considerable damage to the metastable penumbral tissue. Adaptive immunity is deeply involved in the central and peripheral events triggered by cerebral ischemia, but whether a classical autoimmune response against brain antigens unveiled by tissue damage contributes to the acute phase of the damage is still unknown. Lymphocytes invade the ischemic brain and contribute to tissue damage, but the rapidity of their deleterious effect is not consistent with an females and in aging, protection in the presence of cardiovascular risk factors and efficacy in higher-order species need further exploration. Nevertheless, the powerful protective effects of immunomodulators justify additional investigations in this direction.
The recent identification of IL-17-secreting T cells as a crucial effector of the tissue damage in autoimmune diseases (T H 17 cells) 104 and cerebral ischemia (gdT cells) 41 raises the possibility that counteracting IL-17 could be beneficial in cerebral ischemia as it is in experimental allergic encephalomyelitis 104 . Boosting the protective roles of T reg cells could also be beneficial 42 , although a destructive role of these cells has also been proposed 105 . These approaches would be desirable because they target the delayed phase of the injury and are anticipated to have a particularly wide therapeutic window. Nevertheless, the role of lymphocytes in ischemic injury is poorly understood, and the full implications of suppressing the action of specific T and B cell populations remain to be defined.
Fighting inflammation: a double-edged sword? Immune cells and inflammation play a key part in tissue repair and reorganization. These beneficial effects have to be considered in developing therapeutic approaches aimed at restraining post-ischemic inflammation. The concern is that although counteracting the inflammatory response to ischemic injury may ameliorate the tissue damage in the acute phase, it may also compromise repair mechanisms and worsen the long-term outcome of the injury. Owing to the paucity of experimental studies in the recovery phase, there is no definitive experimental evidence that anti-inflammatory treatments interfere with repair processes in the postischemic brain. However, prosurvival effects of immune cells stemming from growth factor production, neurogenesis and neuroplasticity are well established ( Table 2) 105 . The essential role of inflammation in tissue repair highlights the difficulties with approaches based on full-blown ROS, NO, the complement system, apoptosis-inducing receptors and the perforin pathway represent the major effectors of cell death in inflammation.
ROS and NO. In the setting of inflammation, O 2 -is produced mainly by NADPH oxidase, an enzyme expressed in virtually all inflammatory cells (Boxes 2 and 3) . At the same time, large amounts of NO are produced by de novo expression of iNOS 89 . NO reacts preferentially with O 2 -to form the cytotoxic molecule peroxynitrite. H 2 O 2 is derived from O 2 -dismutation and gives rise to highly toxic hydroxyl radicals via the Haber-Weiss reaction, facilitated by the increased availability of free iron in ischemia 123 . These toxic molecules alter cellular proteins, lipids and ribonucleic acids, leading to cell dysfunction or death, and they have been implicated in the tissue damage produced by post-ischemic inflammation. For example, suppression of NADPH oxidase or iNOS activity protects the brain in the late phase of cerebral ischemia (Supplementary Table 1 ).
The complement system. The complement system is a proteolytic cascade composed of several subunits (C1 through C9) that leads to cell lysis via the formation of a pore-like structure assembled from C9 termed the membrane attack complex. Complement also enhances phagocytosis (opsonization), or acts as a chemotactic-activating stimulus for inflammatory cells. After ischemia, complement is activated, and its components are either upregulated in glia and neurons or enter the brain through BBB breakdown 136 . The involvement of complement in ischemic damage
BOX 4 How does inflammation kill?
is indicated by the fact that deletion of endogenous complement inhibitors increases brain injury, whereas their upregulation or administration is protective (Supplementary Table 1 ).
Apoptosis inducing receptors. Fas (CD95), a member of the TNF receptor superfamily, is expressed on neurons and glia after ischemia 129 , whereas its ligand FasL (CD95L) is present in neurons, microglia cytotoxic T cells, gdT cells and NK cells 137 . Fas ligation results in formation of the death-inducing signaling complex and subsequent activation of caspase-8 and of the proapoptotic factor Bid. Similarly, the TNF-related apoptosisinducing ligand (TRAIL) is expressed de novo after ischemia in astrocytes and microglia 138 , and it induces apoptosis by engaging its receptors on neurons and glia. This pathway is involved in ischemic cell death, because TRAIL inhibition or Fas mutation ameliorates ischemic injury 138, 139 .
Perforin and granzyme. This pathway is used by cytotoxic T cells, NKT and NK cells, which release perforin and granzyme upon molecular recognition of antigen associated with MHC class I or class I-like molecules. After engagement of accessory surface receptors, such as ICAM-1, degranulation occurs releasing the protease granzyme, perforin, which is analogous to the complement subunit C9, and the proteoglycan serglycin. This complex is internalized by the target cell, where granzyme triggers apoptosis by activating caspase-3 and Bid. The involvement of this pathway in ischemic brain injury is suggested by observations that genetic deletion of perforin is protective 140 . r e v i e w adaptive immune response targeted to the brain. Remarkably, selected lymphocyte subpopulations are protective, acting to dampen the cytotoxic effects of other inflammatory cells and promoting tissue recovery. The mechanistic bases for this dichotomous response of lymphocytes remains to be elucidated (Fig. 3) . Although the participation of inflammation and immunity in tissue recovery is well established in other organs, very little is known about these processes in the brain. Even less clear are the long-term effects of the adaptive immune response associated with stroke and their role in the sequelae of ischemic damage, such as brain atrophy and dementia. Similarly, it is unclear whether the immune system develops a memory of the antigen exposure and whether an autoimmune response develops after subsequent exposure to the same antigen, as it may occur in cases of recurrent strokes. Although much has been learned on the interplay between the peripheral immunosuppression and the central immune activation associated with stroke, their impact on short-and long-term tissue outcome remains poorly understood. The fact that the immune system and inflammation are central to the pathophysiology of stroke has raised the prospect of new therapeutic approaches to counteract ischemic injury. However, understanding of the crosstalk between the immune system and the ischemic brain is still rudimentary and, as suggested by failed clinical trials, not adequate to guide therapeutic interventions. Modulation of adaptive immunity may afford the opportunity to deviate the post-ischemic immune response away from tissue damage and toward protection, an approach very effective in stroke models. But immunomodulation can also have deleterious effects that need to be considered.
The remarkable impact that modulation of the immune system has on stroke damage and repair justifies the aggressive pursuit of basic and clinical investigations seeking to unravel the fundamental processes governing the interaction of the ischemic brain with the immune system.
